ArticleBMC cancer2026
Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study.World journal of surgical oncology · 2026Trial
- Ternary MOF-PEDOT: PSS/AuNPs nanocomposite for ultrasensitive electrochemical detection of extracellular vesicles.Mikrochimica acta · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCurrent tissue-based biomarkers for gastric cancer (GC) immunotherapy face significant limitations due to tumor heterogeneity and sampling constraints. This study explores plasma proteome profiling as a non-invasive strategy to identify dynamic biomarkers predictive of treatment response.
methodsIn a prospective cohort of 88 advanced GC patients receiving immunotherapy, we performed longitudinal plasma proteomic analysis at baseline and during cycles 2 and 4. Ridge regression was employed to develop composite protein scores, which were validated using Cox models and Kaplan-Meier analyses. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), as well as biomarker dynamics, were assessed over a median follow-up period of 12.9 months.
resultsA baseline composite score integrating IFN-gamma, CSF-1, MIC-A/B, and ANGPT demonstrated superior discriminative power for immunotherapy response (area under the ROC curve [AUC]) = 0.77, 95% confidence intervals [CI]: 0.67-0.88) compared to individual markers. Elevated baseline levels of IFN-gamma correlated with prolonged PFS (upper median vs. lower median: Hazard ratios [HR] = 0.67, P = 0.007) and OS (HR = 0.64, P = 0.012). Longitudinal monitoring revealed the dynamics pattern of IFN-gamma: early elevation predicted durable clinical benefit (DCB) (median PFS: not evaluable vs. 6.7 months in no-durable benefit [NDB]), while a persistent decrease post-cycle 4 indicated a risk of relapse (P = 0.028).
conclusionIFN-gamma emerges as a critical biomarker for prognostic assessment and therapeutic monitoring in advanced GC immunotherapy, and its composite model incorporating PD-L1 Combined Positive Score (CPS) demonstrated superior predictive efficacy, highlighting the necessity for validating additional biomarkers in future clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.